For adult diffuse gliomas (ADGs), most grading can be achieved through molecular subtyping, retaining only two key histopathological features for high-grade glioma (HGG): necrosis (NEC) and microvascular proliferation (MVP). We developed a deep learning (DL) framework to automatically identify and characterize these features. We trained patch-level models to detect and quantify NEC and MVP using a dataset that employed active learning, incorporating patches from 621 whole-slide images (WSIs) from the Chinese Glioma Genome Atlas (CGGA). Utilizing trained patch-level models, we effectively integrated the predicted outcomes and positions of individual patches within WSIs from The Cancer Genome Atlas (TCGA) cohort to form datasets. Subsequently, we introduced a patient-level model, named PLNet (Probability Localization Network), which was trained on these datasets to facilitate patient diagnosis. We also explored the subtypes of NEC and MVP based on the features extracted from patch-level models with clustering process applied on all positive patches. The patient-level models demonstrated exceptional performance, achieving an AUC of 0.9968, 0.9995 and AUPRC of 0.9788, 0.9860 for NEC and MVP, respectively. Compared to pathological reports, our patient-level models achieved the accuracy of 88.05% for NEC and 90.20% for MVP, along with a sensitivity of 73.68% and 77%. When sensitivity was set at 80%, the accuracy for NEC reached 79.28% and for MVP reached 77.55%. DL models enabled more efficient and accurate histopathological image analysis which will aid traditional glioma diagnosis. Clustering-based analyses utilizing features extracted from patch-level models could further investigate the subtypes of NEC and MVP.

The authors have declared no competing interest.

Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. R6003-22)； ITC grant (MHP/004/19, ITCPD/17-9)； Big Data for Bio-Intelligence Laboratory (Z0428)

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors